NASDAQ: JSPRJasper Therapeutics Inc Stock
$0.46-0.01 (-2.13%)
Updated Jun 12, 2026
JSPR Price
$0.46
Fair Value Price
N/A
Market Cap
$12.82M
52 Week Low
$0.42
52 Week High
$7.19
P/E
-0.17x
P/B
3.77x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$55.73M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
5.23
Operating Cash Flow
-$69M
Beta
0.84
Next Earnings
Aug 13, 2026
Ex-Dividend
N/A
Next Dividend
N/A
JSPR Overview
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for hematopoietic stem cell transplantation and gene therapies. Its core mission is to develop and commercialize conditioning agents and advanced stem cell engineering methods. These advancements aim to expand the utility of stem cell transplantation and ex vivo gene therapy, a process involving genetic modification of cells outside the body before their transplantation. JSP191 stands as the company's leading investigational product, currently in clinical development. This conditioning antibody functions by ablating hematopoietic stem cells from patients' bone marrow as a prerequisite for allogeneic stem cell or stem cell gene therapy. Additionally, Jasper is creating engineered hematopoietic stem cell product candidates intended to address significant limitations inherent in both allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine JSPR's potential to beat the market
- JSPR doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
JSPR
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $230.56 | A | |
| $53.13 | A | |
| $15.82 | A |
Be the first to know about important JSPR news, forecast changes, insider trades & much more!
JSPR News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how JSPR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
JSPR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
JSPR is good value based on its book value relative to its share price (3.77x), compared to the US Biotechnology industry average (4.85x)
P/B vs Industry Valuation
JSPR is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more JSPR due diligence checks available for Premium users.
Valuation
JSPR fair value
Fair Value of JSPR stock based on Discounted Cash Flow (DCF)
Price
$0.46
Fair Value
$1.79
Undervalued by
74.31%
JSPR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
JSPR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.17x
Industry
16.53x
Market
14.15x
JSPR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.77x
Industry
4.85x
JSPR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
JSPR's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.2M
Profit Margin
0%
JSPR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$21.2M
Liabilities
$17.8M
Debt to equity
5.23
JSPR's short-term assets ($20.29M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
JSPR's short-term assets ($20.29M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
JSPR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
JSPR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$14.5M
Investing
$0.0
Financing
$0.0
JSPR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
JSPR vs Biotech Stocks
Jasper Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.